The performance of companies tied to the drug's past presents a complex investment picture . While the initial boom generated substantial returns , generic alternatives have significantly diminished revenue. Investing in associated pharmaceutical companies now requires a careful assessment of proprietary protection , evolving healthcare shifts , an